€10.50
+0.00 (+0.00%)
EUR · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALM.MC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
54 interventional · 11 observational · 20 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic DermatitisNCT06815380observationalAbsolute Measures in the Overall Health-related Well-being Index Evaluated Through World Health Organization (WHO-5) Score Throughout the Study Observation Period | — | Recruiting | Other: No Intervention | Atopic Dermatitis, Eczema | 1,000 | Mar 2029 | ≤ 954 d | 2025-02-07 |
| A Study of Lebrikizumab in Adults With Nummular EczemaNCT07542483Percentage of Participants Achieving Investigator Global Assessment (IGA) Score of 0 or 1 and a >=2-point Reduction from Baseline at Week 24Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Lebrikizumab · Other: Placebo | Nummular Eczema | 270 | Aug 2028 | ≤ 742 d | 2026-08-17 |
| A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or ScalpNCT05387525Percentage of Participants with Histologically Confirmed Invasive Squamous Cell Carcinoma (SCC) in the Treatment Field (TF)Randomized · Single-masked · Treatment | Phase 4 | Active, not recruiting | Drug: Tirbanibulin (Klisyri®) 10 mg/g ointment, Diclofenac Sodium 3% Gel | Keratosis, Actinic | 447 | Jul 2027 | ≤ 345 d | 2025-02-11 |
| A Study of LAD603 in Adults With Alopecia AreataNCT07311564Percent Change from Baseline in the Severity of Alopecia Tool (SALT) ScoreRandomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: LAD603 · Other: Placebo | Alopecia Areata | 136 | 2027-06-23 | in 307 d | 2026-05-20 |
| A Study of LAD106 in Healthy Adult ParticipantsNCT07471932Part A (SAD): Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEsRandomized · Triple-masked · Treatment | Phase 1 | Recruiting | Drug: LAD106, Lebrikizumab · Other: Placebo | Healthy Volunteers | 93 | 2027-05-31 | in 284 d | 2026-05-15 |
| A Study of LAD191 in Adults With Hidradenitis SuppurativaNCT07151937Proportion of Participants Achieving 50 Percent (%) Reduction from Baseline in Hidradenitis Suppurativa Clinical Response (HiSCR-50)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: LAD191, Adalimumab · Other: Placebo | Hidradenitis Suppurativa | 200 | 2027-05-25 | in 278 d | 2026-05-11 |
| A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisNCT06526182Part 1: Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Score Less than or Equal to (<=) 7 at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Biological: Lebrikizumab · Other: Placebo | Dermatitis, Atopic, Eczema | 520 | 2027-04-25 | in 248 d | 2026-04-21 |
| A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis SuppurativaNCT07547813Proportion of Participants Achieving 55 Percent (%) Reduction from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4-55)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: LAD328 · Other: Placebo | Hidradenitis Suppurativa | 50 | Feb 2027 | ≤ 192 d | 2026-08-17 |
| A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)NCT06029257observationalPercentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of "Clear" (0) or "Almost Clear" (1) | — | Recruiting | Drug: Tildrakizumab | Genital Psoriasis | 110 | Mar 2026 | — | 2025-01-29 |
| A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live SettingNCT06488170observationalChange From Baseline in 5-item World Health Organization Wellbeing Index (WHO-5) Score | — | Active, not recruiting | Drug: Tildrakizumab | Plaque Psoriasis | 42 | Jan 2026 | — | 2025-06-24 |
| A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque PsoriasisNCT06030076observationalTreatment Satisfaction Questionnaire for Medication-11 (TSQM-11) Score | — | Recruiting | Drug: Tildrakizumab | Plaque Psoriasis | 50 | Oct 2025 | — | 2025-01-29 |
| Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic DermatitisNCT05916365Proportion of the Participants who will Discontinue from Study Treatment due to Treatment-emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 3 | Completed | Biological: Lebrikizumab | Atopic Dermatitis | 174 | 2026-04-23actual | — | 2026-05-14 |
| Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisNCT05990725results2026-07-17Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Lebrikizumab | Atopic Dermatitis, Eczema | 260 | 2025-06-25actual | — | 2026-07-17 |
| A Single and Multiple Ascending Dose Study of LAD603 in Healthy SubjectsNCT06200597Part 1: Number of Participants with Adverse Events (AEs) and Severity of AEsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: LAD603 · Other: Placebo | Healthy Volunteers | 92 | 2025-05-11actual | — | 2025-12-17 |
| A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic KeratosisNCT06135415results2026-06-30Percent Change From Baseline in Lesion Count at Day 57Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tirbanibulin · Other: Vehicle ointment | Keratosis, Actinic | 280 | 2025-04-30actual | — | 2026-06-30 |
| Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune DiseaseNCT06488209Part 1: Number of Participants with Adverse Events (AEs) and Severity of AEsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: LAD191 · Other: Placebo | Healthy Volunteers, Autoimmune Disease | 69 | 2025-04-03actual | — | 2025-11-24 |
| Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE StudyNCT04823247observationalChange From Baseline in 5-item World Health Organization Wellbeing Index (WHO-5) Score | — | Completed | Drug: Tildrakizumab | Plaque Psoriasis | 782 | 2025-01-09actual | — | 2025-05-11 |
| A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in AdultsNCT05811234results2025-09-24observationalAbsolute Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9) Domain Total Score at Week 12Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: CAL/BDP PAD Cream | Plaque Psoriasis | 291 | 2024-10-01actual | — | 2025-09-24 |
| Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical PracticeNCT04203693results2026-03-02observationalCohort 1: Absolute Psoriasis Area and Severity Index (PASI) Score at Week 48Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Tildrakizumab | Plaque Psoriasis | 331 | 2024-05-02actual | — | 2026-03-02 |
| A Study of Tirbanibulin on the Wellbeing of Participants With Actinic KeratosesNCT05741294results2025-02-20Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9) Total Score of Each Components at Day 57Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Tirbanibulin 2.5 mg ointment | Actinic Keratosis | 334 | 2024-01-19actual | — | 2025-02-20 |
| A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for CyclosporineNCT05149313results2024-11-06Double-blind Induction Period: Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) 75 (>=75% Reduction From Baseline in EASI Score) at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Lebrikizumab · Drug: Lebrikizumab-matching Placebo | Dermatitis, Atopic, Eczema | 331 | 2023-01-30actual | — | 2025-05-20 |
| A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic KeratosisNCT05279131results2024-01-23Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 5Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tirbanibulin ointment 1% | Keratosis, Actinic | 105 | 2022-12-28actual | — | 2024-01-23 |
| Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic KeratosisNCT05260073results2024-09-20observationalChange From Baseline in Domain Scores Using the Patient Reported Outcome Skindex-16 Instrument at Week 8Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Tirbanibulin | Keratosis, Actinic | 300 | 2022-10-31actual | — | 2024-09-20 |
| UV Sensor in Patients With Actinic KeratosisNCT05481073observationalQOL UV sensor | — | Completed | Device: UV sensor | Keratosis, Actinic | 10 | 2022-08-02actual | — | 2022-11-14 |
| Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)NCT04820673results2024-10-10observationalChange From Baseline in Acne Symptom and Impact Scale Questionnaire (ASIS) Domain Score at Week 12Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Sarecycline | Acne Vulgaris | 300 | 2022-05-04actual | — | 2024-10-10 |
| Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate TherapyNCT04263610Part 2: Percentage of Participants Achieving a Psoriasis Area Severity Index 75 (PASI 75) after Tildrakizumab Treatment at Week 40Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Dimethyl fumarate (DMF) standard scheme, Dimethyl fumarate (DMF) simplified scheme, Tildrakizumab | Plaque Psoriasis | 190 | 2022-02-16actual | — | 2022-05-27 |
| Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)NCT04229836Absolute Psoriasis Area and Severity Index (PASI) Score at Week 24Open-label · Treatment | Phase 4 | Completed | Drug: Tildrakizumab 100 mg Solution for Injection | Plaque Psoriasis | 178 | 2021-11-15actual | — | 2023-03-03 |
| Study of Pidotimod in Children With Recurrent Respiratory Tract Infections (RRI)NCT04322669Rate of Respiratory Tract Infection (RI) per Month During Overall Study PeriodRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Pidotimod, Placebo | Recurrent Respiratory Tract Infections | 338 | 2021-11-04actual | — | 2022-02-02 |
| Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque PsoriasisNCT04339595Number of Participants with Presence of Blood Inflammatory Biomarkers at BaselineOpen-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Low Recruitment | Biological: Tildrakizumab | Plaque Psoriasis | 47 | 2020-07-31actual | — | 2021-12-08 |
| A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)NCT03285490results2021-03-10Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) LesionsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: KX2-391 Ointment 1%, Placebo | Actinic Keratosis | 351 | 2018-05-07actual | — | 2021-03-10 |
| A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or ScalpNCT03285477results2021-03-10Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) LesionsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Placebo, KX2-391 Ointment 1% | Actinic Keratoses | 351 | 2018-05-03actual | — | 2021-04-13 |
| Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne VulgarisNCT02959970results2020-02-13Number of Participants With Adverse Events (AE)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: dapsone gel | Acne Vulgaris | 100 | 2018-03-09actual | — | 2020-03-03 |
| Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of AcneNCT02320149results2018-05-17Absolute Change in Facial Inflammatory Lesion Counts at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sarecycline, Placebo | Acne Vulgaris | 968 | 2017-02-01actual | — | 2019-02-15 |
| Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of AcneNCT02322866results2018-05-07Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 12Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Sarecycline, Placebo | Acne Vulgaris | 1,034 | 2017-01-12actual | — | 2019-02-01 |
| Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or ScalpNCT02838628results2021-04-14Percentage of Participants With Complete Response of Actinic KeratosisNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: 50 mg of KX2-391 Ointment 1%, 50 mg of KX2-391 Ointment 1% | Actinic Keratosis | 168 | 2017-01-11actual | — | 2021-04-14 |
| Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008NCT02955693Area under the concentration-time curve from zero to time t (AUC(0-t)) of LAS41008 120 mg/Fumaderm® 120 mgRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: LAS41008 120 mg / Fumaderm® 120 mg | Psoriasis | 32 | Oct 2016actual | — | 2016-12-22 |
| A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne VulgarisNCT02413346results2018-05-04Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Sarecycline | Acne Vulgaris | 490 | 2016-08-26actual | — | 2019-02-01 |
| Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic KeratosesNCT02289768Percentage of patients with complete clinical clearance of actinic keratosis lesions in the treatment fieldRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: 5-fluorouracil/salicylic acid, Vehicle | Actinic Keratosis | 166 | Sep 2015actual | — | 2016-08-05 |
| A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate PsoriasisNCT02180464Total symptom scoreRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: LAS41004, control | Psoriasis | 40 | Dec 2014actual | — | 2015-06-10 |
| LAS41008 in Moderate to Severe Chronic Plaque PsoriasisNCT01726933PASI 75Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: LAS41008, LASW1835, Placebo | Plaque Psoriasis | 839 | Oct 2014actual | — | 2015-12-02 |
| A Safety and Efficacy Study of Dapsone Gel in Patients With Acne VulgarisNCT01974141results2017-02-06Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Dapsone Gel, Dapsone Gel Vehicle | Acne Vulgaris | 2,102 | Oct 2014actual | — | 2018-10-09 |
| Safety and Efficacy Study of Dapsone Gel in Patients With Acne VulgarisNCT01974323results2017-02-06Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Dapsone Gel, Dapsone Gel Vehicle | Acne Vulgaris | 2,238 | Oct 2014actual | — | 2018-10-09 |
| Photoallergy Potential of Dapsone Gel in Healthy VolunteersNCT02117739Photoallergic (Sensitizing) Potential Using a Visual ScaleTriple-masked · Treatment | Phase 1 | Completed | Drug: dapsone gel, dapsone gel vehicle | Healthy Volunteers | 58 | Jul 2014actual | — | 2018-10-09 |
| Dermal Tolerability of Dapsone Gel in Healthy VolunteersNCT02117752Mean Cumulative Irritation Index During Induction PhaseRandomized · Single-masked · Treatment | Phase 1 | Completed | Drug: dapsone gel, dapsone gel vehicle, sodium lauryl sulfate, Normal saline | Healthy Volunteers | 237 | Jul 2014actual | — | 2018-10-09 |
| A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and CorticosteroidNCT02094274Change from baseline (pre-dose at each period) in normalised forced expiratory volume in 1 second (FEV1) area under the curve (AUC) over the 12 hour period after IMP administration (AUC0-12)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: LAS40468, Salmeterol/fluticasone propionate, Placebo | Asthma | 30 | May 2014actual | — | 2014-05-22 |
| Phototoxicity Test of Dapsone Gel in Healthy VolunteersNCT02108483Phototoxicity Irritation Potential Using a Visual ScaleTriple-masked · Treatment | Phase 1 | Completed | Drug: dapsone gel, dapsone gel vehicle | Healthy Volunteers | 33 | May 2014actual | — | 2018-10-09 |
| Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque TestNCT02111499Area under the curve, AUC, of the width of the echo-lucent band based on sonography measurementsRandomized · Double-masked · Treatment | Phase 1/2 | Completed | Drug: LAS41004-IMP1, LAS41004 IMP2, LAS41004 IMP3, LAS41004 IMP4, LAS41004 IMP6, LAS41004 IMP5 | Psoriasis | 18 | May 2014actual | — | 2014-06-09 |
| Efficacy and Safety of Tazarotene Gel in Nail PsoriasisNCT02235480% reduction in the Nail Psoriasis Severity Index ( NAPSI )Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Experimental Tazarotene Gel, Placebo | Nail Psoriasis | 66 | May 2014actual | — | 2015-06-10 |
| Neurophysiological Study of Sativex in Multiple Sclerosis (MS) SpasticityNCT01538225H/M reflex ratioRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Sativex®, Placebo | Multiple Sclerosis | 45 | Nov 2013actual | — | 2014-01-20 |
| Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPDNCT01915784Percentage of patients who prefer Genuair® (Pressair™) versus Breezhaler® (Neohaler™) at Visit 2Randomized · Open-label | Phase 3 | Completed | Device: Genuair®, Breezhaler® | Chronic Obstructive Pulmonary Disease (COPD) | 128 | Oct 2013actual | — | 2015-05-29 |
| Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne VulgarisNCT01628549results2019-01-08The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final VisitRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: 50 mg P005672-HCl, Placebo, 100 mg P005672-HCl | Acne Vulgaris | 285 | 2012-11-16actual | — | 2019-02-01 |
| Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic KeratosisNCT01265602superiority of LAS41007 compared to vehicleRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: LAS41007, LASW1510, vehicle of LAS41007 | Actinic Keratosis | 889 | Mar 2012actual | — | 2012-07-24 |
| LAS41005 in Hyperkeratotic Actinic KeratosisNCT01358851Histological status (AK diagnosis and grade) of one predefined target lesionRandomized · Open-label · Treatment | Phase 2 | Completed | Procedure: Cryotherapy · Drug: LAS41005 | Actinic Keratosis | 67 | Mar 2012actual | — | 2015-05-29 |
| Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed PatientsNCT01385696results2013-04-22Percentage of Patients Who Prefer Genuair Device Versus Handihaler Device at Visit 2Randomized · Open-label | Phase 3 | Completed | Device: Genuair® (Almirall S.A.), HandiHaler® (Boehringer Ingelheim's) | Chronic Obstructive Pulmonary Disease (COPD) | 130 | Jan 2012actual | — | 2015-06-24 |
| Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque TestNCT01462643Decrease of skin thickness(AUC, area under the curve)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: LAS41004 | Psoriasis | 22 | Sep 2011actual | — | 2011-10-31 |
| Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida InfectionsNCT01102387Clinical efficacy and mycological cultureRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: LAS41003, LAS189962, LAS189961 | Candidiasis | 137 | Jul 2011actual | — | 2012-07-04 |
| Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque TestNCT01360944Decrease in thickness of infiltrationRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: LAS41004, reference | Psoriasis | 22 | Jun 2011actual | — | 2015-06-08 |
| Clinical Trial to Investigate Efficacy of LAS41004 in PsoriasisNCT01283698Decrease in thickness of infiltrationRandomized · Single-masked · Treatment | Phase 2 | Completed | Drug: Experimental: LAS 41004 dosage 1, Experimental: LAS 41004 dosage 2, Experimental: LAS 41004 dosage 3, Placebo Comparator: placebo, Reference | Psoriasis | 20 | Mar 2011actual | — | 2015-05-29 |
| Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of PsoriasisNCT01119339Decrease in skin thicknessRandomized · Single-masked · Treatment | Phase 2 | Completed | Drug: LAS 41004, LAS 41004, LAS 41004, LAS 41004, LAS 41004, LAS 41004 dosage 6, Placebo, Reference | Psoriasis | 20 | Sep 2010actual | — | 2015-05-29 |
| Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected EczemaNCT01020994Combination of clinical and microbial treatment successRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: LAS41003, LAS189962, LAS189961 | Eczema | 150 | Jun 2010actual | — | 2010-07-09 |
| Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea PedisNCT01096472Clinical assessment scores and mycological status of fungi (KOH test and mycological culture)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: LAS41003, LAS189961, LAS189962 | Tinea Pedis | 120 | Jun 2010actual | — | 2012-07-09 |
| Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic EczemaNCT01119313Change in total sum score of Clinical signsRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: LAS 41002, Active | Atopic Eczema | 20 | Mar 2010actual | — | 2010-07-12 |
| Efficacy and Safety Study of LAS41007 in the Treatment of Actinic KeratosisNCT00991861Histological clearance of one pre-selected target lesionRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: LAS41007 o.d., LAS41007 b.i.d., LAS106521 | Actinic Keratosis | 100 | Feb 2010actual | — | 2015-05-29 |
| Study on the Efficacy of LAS41005 in the Treatment of Actinic KeratosisNCT00987246Histological status of AK target lesionRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Placebo Gel, LAS41005, LAS106521 | Actinic Keratosis | 470 | Jun 2009actual | — | 2015-07-28 |
| Standardized sTudy With Almotriptan in eaRly Treatment of MigraineNCT00725140observationalPain Free | — | Completed | — | Migraine | 501 | Apr 2009actual | — | 2015-06-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19